Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
4.580
+0.120 (2.69%)
At close: Jun 6, 2025, 4:00 PM
4.630
+0.050 (1.09%)
After-hours: Jun 6, 2025, 7:45 PM EDT
Xeris Biopharma Holdings Revenue
Xeris Biopharma Holdings had revenue of $60.12M in the quarter ending March 31, 2025, with 47.94% growth. This brings the company's revenue in the last twelve months to $222.55M, up 29.88% year-over-year. In the year 2024, Xeris Biopharma Holdings had annual revenue of $203.07M with 23.89% growth.
Revenue (ttm)
$222.55M
Revenue Growth
+29.88%
P/S Ratio
3.08
Revenue / Employee
$564,850
Employees
394
Market Cap
733.51M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
XERS News
- 4 days ago - Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day - Business Wire
- 18 days ago - Xeris Announces Details for Analyst & Investor Day - Business Wire
- 4 weeks ago - Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Xeris Biopharma Reports Record First Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings - Seeking Alpha
- 5 weeks ago - Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 - Business Wire
- 2 months ago - Xeris Announces Changes to Its Board of Directors - Business Wire
- 2 months ago - Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid - Business Wire